Next-generation sequencing (NGS) and microarray technologies are essential resources for investigating the genomic and molecular underpinnings of cancer formation, progression, and clinical outcomes. The primary objective of the Cancer Genomics Shared Resource (CGSR) is to maximize the scientific and clinical impact of research by Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) members. This is accomplished by providing rapid and cost-effective access to state-of-the-art genomic technologies, while creating a unifying environment that cultivates scientific awareness, education, and collaboration. The CGSR supports the WFBCCC's mission by providing cancer-prioritized access to comprehensive microarray and NGS technologies and offers seamless data flow through to the Biostatistics and Bioinformatics Shared Resource - for bioinformatics support. In October 2014, at the instigation of Director Pasche, the former Microarray Core Laboratory (2002-2014; which received a score of ?excellent? in the prior critique) was renamed the Cancer Genomics Shared Resource to reflect the integration of the WFBCCC's microarray core competencies with the NGS expertise of the Center for Genomics and Personalized Medicine Research. This new joint-Center partnership reflects the strategic plans of the WFBCCC and the Wake Forest School of Medicine (WFSOM), as well as supporting priority recommendations of the WFSOM Centers and Cores Advisory Committee. The CGSR provides cutting-edge genomic services, prioritizes cancer-specific research, creates an optimal environment for the Institution's rapidly developing precision medicine initiative, and seamlessly integrates with other key Shared Resources within the WFBCCC to promote integrated, high-quality workflows for cancer genomics research. The CGSR is led by Co-Directors Lance Miller, Ph.D., and Greg Hawkins, Ph.D., who have established records in cancer genomics research, and is operated by four experienced technicians (two at 100% effort, one at 50% effort and one at 5% effort). A bioinformatician devotes 30% of effort to CGSR daily operations. In the most recent grant year (11/01/14-10/31/15), the CGSR operated at 80-90% FTE utilization to provide 1,144 services to 20 investigators, 75% of which were WFBCCC investigators. Compared to previous years, the CGSR doubled its service output and increased its cancer-specific service output by approximately 50%. The CGSR directly contributes to the scientific achievements of WFBCCC investigators by generating high-quality and cost-effective data that will translate into new discoveries, publications, grant awards, and grant applications. Further development of CGSR's role in supporting the development and productivity of WFBCCC Disease-Oriented Teams and the continued development of seamless workflows across Shared Resources are expected to enhance translational genomics initiatives at the WFBCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA012197-42
Application #
9209686
Study Section
Special Emphasis Panel (NCI (K1)-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
42
Fiscal Year
2017
Total Cost
$124,102
Indirect Cost
$44,036
Name
Wake Forest University Health Sciences
Department
Type
Domestic Higher Education
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373
Zhao, Yan; Li, Fang; Mao, Chengqiong et al. (2018) Multiarm Nanoconjugates for Cancer Cell-Targeted Delivery of Photosensitizers. Mol Pharm 15:2559-2569
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Xiao, Jiajie; Melvin, Ryan L; Salsbury Jr, Freddie R (2018) Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning. J Biomol Struct Dyn :1-18
Mao, Chengqiong; Zhao, Yan; Li, Fang et al. (2018) P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release 286:289-300

Showing the most recent 10 out of 548 publications